Key result
Adult HF therapies appear less effective in children due to unique phenotypic and molecular differences.
Pediatric heart failure requires specific therapeutic approaches rather than relying on adult-based therapies due to distinct pathophysiological differences.
There have been many advances in the treatment of heart failure over the past several years. While these advancements have resulted in improved outcomes in adults with heart failure, these same treatments do not seem to be as efficacious in children with heart failure. Investigations of the failing pediatric heart suggest that there are unique phenotypic, pathologic and molecular differences that could influence how children with heart failure response to adult-based therapies. In this review, several recent studies and the potential implications of their findings on informing the future of the management of pediatric heart failure are discussed.
No takes yet. Share an insight, caveat, or question.
A 2011 study conducted a review in Pediatric heart failure / dilated cardiomyopathy. Adult-based heart failure therapies was evaluated. Adult-based heart failure therapies appear less efficacious in children due to unique phenotypic, pathologic, and molecular differences in the failing pediatric heart.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: